Fibrinolytic therapy for vasculitis of atrophie blanche

Gilliam, J. N.

doi:10.1001/archderm.109.5.664

Archives of Dermatology

1974

DOI: 10.1001/archderm.109.5.664

|View full text |Cite

Fibrinolytic therapy for vasculitis of atrophie blanche

J. N. Gilliam¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1980

2003

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 15 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3,4 In the literature, several therapeutic approaches have been recommended by different authors to treat these patients. These methods have included fibrinolytic agents (phenformin, ethylestrenol), 4,5 anticoagulants [aspirin, dipyridamole, pentoxifylline, danazol, low-dose heparin, tissue plasminogen activator (t-PA)], [6][7][8][9][10] vasodilators (nicotinic acid, nifedipine, sulfasalazine), 11,12 psoralen plus ultraviolet A and intravenous immunoglobulin (IVIg). 13,14 A combination of aspirin and dipyridamole plus resting and local wound care is currently the most practised treatment.…”

mentioning

confidence: 99%

Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen

Yang¹,

Ho²,

Chan³

et al. 2003

Br J Dermatol

View full text Add to dashboard Cite

We describe a new method for treating livedoid vasculopathy. The typical presentation of livedoid vasculopathy includes chronic, recurrent painful ulcers, satellite scar-like atrophy and telangiectasia involving the lower extremities. Histologically, these lesions show areas of ulceration and dermal vessel occlusion without frank inflammatory cell infiltration. There is currently no satisfactory therapy available for this disease. Hyperbaric oxygen (HBO) has recently established itself as one of the most effective methods of treating ischaemic wounds, including diabetic ulcers. We used this therapy in two patients whose lesions were resistant to multiple therapeutic modalities. Not only did their ulcers respond rapidly to the HBO therapy, but the disturbing wound pain also resolved at the same time. To our knowledge, this is the first successful trial of HBO therapy in livedoid vasculopathy. We believe this to be a very promising new therapy for livedoid vasculopathy and to be worth further investigation.

show abstract

mentioning

confidence: 99%

Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen

Yang¹,

Ho²,

Chan³

et al. 2003

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…The prevalence is estimated around 1:100 000 per year and is more frequent in young women (1:3). 5 On the basis of the clinical evolution, the improvement during fibrinolytic and anti- platelet therapy, [6][7][8] and the detection of elevated serum fibrinopeptide A levels, 2 LV is thought to be mediated by a vasocclusive mechanism. Nevertheless, specific histological findings, such as thickened blood vessel walls, occasional deposition of immunoreactants, and fibrin, 9 and the possible association with immune-mediated diseases suggest a potential pathogenetic role of immunological mechanisms.…”

mentioning

confidence: 99%

Livedo Vasculopathy vs Small Vessel Cutaneous Vasculitis

Papi¹,

Didona²,

Pità³

et al. 1998

Arch Dermatol

100

View full text Add to dashboard Cite

To assess the role of platelets and lymphocyterelated immunological mechanisms in livedo vasculopathy (LV) and cutaneous small vessel vasculitis (CSVV). Livedo vasculopathy is thought to be related to the thrombotic occlusion of small and medium-sized dermal vessels. Cutaneous small vessel vasculitis comprises a heterogeneous group of disorders in which the main pathogenetic events could be modulated by circulating cytokines.Design: Case series study of 2 groups of patients affected respectively with LV and CSVV. Setting: A large clinical and research institute for the study and treatment of cutaneous diseases. Patients: Consecutive patients with clinically and histologically proved idiopathic LV (n = 8) and CSVV (n = 20) were studied and compared with healthy donors (n = 20). Patients with potentially correlated systemic diseases were excluded. Main Outcome Measures: Surface expression of platelet P-selectin and circulating level of interleukin (IL) 1␤, tumor necrosis factor ␣ (TNF-␣), IL-8, IL-2, and soluble IL-2 receptor.Results: The IL-2 and soluble IL-2 receptor levels were significantly higher in serum samples from patients with

show abstract

A clinical approach to systemic vasculitis

Fan

Davis

Somer

et al. 1980

Seminars in Arthritis and Rheumatism

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Fibrinolytic therapy for vasculitis of atrophie blanche

Cited by 15 publications

References 0 publications

Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen

Intractable livedoid vasculopathy successfully treated with hyperbaric oxygen

Livedo Vasculopathy vs Small Vessel Cutaneous Vasculitis

A clinical approach to systemic vasculitis

Contact Info

Product

Resources

About